Story Poster
Photo by Twitter / Cal Basketball
Cal Basketball

Cal Falls To Stanford, 57-50

February 1, 2022
1,700

STANFORD, Calif. (AP) – The California men’s basketball team came up short in a Pac-12 clash with rival Stanford, falling 57-50 at Maples Pavilion on Tuesday night.

Despite low turnover counts (Cal 9, Stanford 7), both teams struggled from the field as the Golden Bears (9-13, 2-9 Pac-12) trailed 21-20 at intermission. Both teams ramped it up in the second half, but Cal never got closer than a two-point deficit with 8:06 remaining in the contest. It was Cal’s eighth straight loss dating back to Jan. 6.

Jordan Shepherd scored a game-high 15 points and Lars Thiemann added 11 points on 3-3 shooting and six rebounds in his first start of the season. Cal was absent Andre Kelly and his 13.4 points and 8.4 rebounds per game due to an ankle injury he suffered in a loss at No. 15 USC last Saturday. It was the first game Kelly missed in his college career, breaking a streak of 113 consecutive games played.

Stanford (13-7, 6-4) shot 42 percent (21-50) to Cal's 35.3 percent (18-51). Stanford missed 12 of 15 3-point attempts and the Bears came up empty from beyond the arc on 11 of 14 tries.

Harrison Ingram's jumper with 34 seconds before halftime gave Stanford the lead for good. Brandon Angel's 3 with 11:23 left capped a 6-0 Stanford spurt for a 35-28 lead.

Thiemann’s three-point play with 8:06 left brought Cal within 37-35. A late second-chance jumper by Jalen Celestine, who scored seven points, cut the deficit to 49-43 with 2:45 remaining.

UP NEXT

Cal will host Washington at 8 p.m. PT on Thursday, Feb. 3 at Haas Pavilion. The game will be televised on the Pac-12 Networks.

Related:

Stanford Preview: Cardinal Has Had Ups and Downs

Discussion from...

Cal Falls To Stanford, 57-50

1,598 Views | 0 Replies | Last: 2 yr ago by Cal Athletics
There are not any replies to this post yet.
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.